Sex linked Genetics
Mrs. K explains sex-linked traits and how to complete punnett squares for sex-linked traits.

By: Meredith Kersting

Read this article:
Sex linked Genetics - Video

Recommendation and review posted by Bethany Smith

Escutcheon - Kill Mode
Taken from the album "Battle Order" (2009) Melodic Death metal inspired by the old Swedisch Gothenburg style LYRICS: Awakening, it #39;s hard to breathe The darkness is surrounding Cannot move, fear returns to pain I close my eyes Drift away, again The fluid is pumped away My lungs are expanding with air As we #39;re brought back to life once again I #39;ll never get used to this, panic will overtake Gasping, shaking, screaming, fighting, free Expanding cells, regaining life, reborn again Bio-genetics will complete this war machine The memories of the fight, so vividly Can #39;t tell the dream from reality Relive the past once more Regiment is going down Big red blur, then it fades away ... fades away Thirty years and the second battle we have just won It #39;s time to go, back to hell and fight for our good cause Not all is lost, Renewed with strength, armor and more men We were meant to fight this war and Victory was ours to take No matter what the cost was going to be Conquer all the worlds, our destiny All worn out, defending armor The reason that I get this chance Another tour, another mission Maybe it #39;s my last and go down in a bang Let #39;s go now and ride out to fight Don #39;t stop, hesitate, give it all Send them back to where they came from Finally... avenge our grief, for so long Approaching the field, pitch black night Switch into kill mode, attack

By: Alwin Bassphyx

See more here:
Escutcheon - Kill Mode - Video

Recommendation and review posted by Bethany Smith

James Gilliland and Giles Campbell, January 8th 2013
*I do not own this work, it belongs to James Gilliland, the world puja network and the great artists who took part in all aspects of it. Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for "fair use" for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use.* bull; Contact with multiple Beings bull; Out of body experiences manifested by meditation bull; Understanding self, realization and forgiveness bull; The struggle with this reality continues...... Giles Campbell has a degree in Zoology and a Masters in Biodiversity and conservation genetics. He worked within the Australian government scientific research organization (CSIRO) for 9-10 years. Over the past five years he has experienced different types of contact with different beings, been followed by lights and this finally led to a great awakening. This transformation accelerated in recent years and months as his life has radically changed and set in a new direction after having had a number of paradigm shattering experiences, including contact with extra dimensional entities and spontaneous out of body experiences. Giles has visited the ECETI Ranch numerous times in 2012 and has traveled to other power points on the planet in his travels. For more information have a look here: - ECETI.org Insulting ...

By: EroSeninka

Read more:
James Gilliland and Giles Campbell, January 8th 2013 - Video

Recommendation and review posted by Bethany Smith

Teresa Edmondson, Natural Health Practitioner
Invitation to our Nutrition Genetics presentation at the Link Centre in Tupelo.

By: Genes Don #39;t Lie

See original here:
Teresa Edmondson, Natural Health Practitioner - Video

Recommendation and review posted by Bethany Smith

Congressional Briefing 2012
A Congressional briefing "The Multi-Generational Impact of Autoimmune Disease: America #39;s Silent Health Crisis" was held March 28th, 2012, at the Rayburn House Office Building on Capitol Hill, in Washington, DC. The briefing to bring national attention to the serious issue of autoimmune disease was co-sponsored by the National Coalition of Autoimmune Patient Groups (NCAPG) and the American Autoimmune Related Diseases Association (AARDA). The briefing opened with Dr. Lindsey Criswell of the University of California who presented "Introduction to the Autoimmune Problem: Genetics and Autoimmune Disease". Next, Dr. Nicole McDonald and her family shared their family #39;s range of members affected with some type of autoimmune disease. Dr. McDonald #39;s teen daughter has Graves #39; disease (thyroid), her mother has ulcerative colitis (an autoimmune disease of the colon), her father has Hashimoto #39;s (thyroid disease), her sister has vitiligo and psoriasis (skin conditions), and her first cousin has Ankylosing Spondylitis (autoimmune degeneration in the backbone). Dr. Robert Phillips, Director of the Center for Coping, in Long Island, NY (familiar to those who have attended past ITP conferences), discussed the emotional and family cost implications of autoimmune diseases. Info via http://www.pdsa.org

By: AARDATube

See the original post here:
Congressional Briefing 2012 - Video

Recommendation and review posted by Bethany Smith

November 2012 GoMRI-III sampling cruise: macroalgae and macrocrustaceans offshore Ewing Bank
This video shows the box dredging leg of the November 16-17, 2012 sampling cruise offshore the northwestern Gulf of Mexico, Stations 5-7 at Ewing Bank (~28o05.146 #39;N, 91o01.66 #39;W) at depths between 54-79 m. The cruise is the field component of the grant "Genetics of the Macondo Oil Spill on Coastal Ecosystems" awarded to Darryl Felder and Suzanne Fredericq from the University of Louisiana at Lafayette, funded by the Gulf of Mexico Research Initiative (GoMRI-1) through the Louisiana University Marine Consortium grant "The Effects of the Macondo Oil Spill on Coastal Ecosystems" Nancy Rabalais, PI. The goal of the research is a critical assessment of post-Deepwater Horizon oil pill impacts on the diversity, vitality, and distribution of offshore benthic seaweeds and macrocrustaceans (and associated fauna) in the NW Gulf of Mexico. The Hourglass-design box dredge provides a now standardized method of semi-quantitative sampling. It is an effective tool only on substrata of low relief that consist of loose rocks and rubble, shells or shell hash, and calcareous nodules (rhodoliths). The expedition departed from LUMCON in Cocodrie LA, on board the R/V Pelican, a 32 m (105ft) ABS Class "A-1+ Oceanographic, steel-hull coastal research vessel operated by UNOLS. Filming and editing by S. Fredericq.

By: nemastoma2

Go here to see the original:
November 2012 GoMRI-III sampling cruise: macroalgae and macrocrustaceans offshore Ewing Bank - Video

Recommendation and review posted by Bethany Smith

Can Lionel Messi be Cloned?
Can Lionel Messi be Cloned? Genetics expert Dr Ricky Joshi gives his stunning verdict. Plus, could you one day buy Messi #39;s left foot from the club #39;s online shop, does Barça DNA exist, and more...

By: NapalmFilm

See the original post here:
Can Lionel Messi be Cloned? - Video

Recommendation and review posted by Bethany Smith

Starchild Skull The New Evidence Lloyd Pye
We would like to thank Andrew Johnson for allowing us to share with you this fantastic talk filmed at "Not on the Six O Clock News" which he hosted in Derby on 30th September 2012. Andrew has very kindly given us permission to upload this talk, however if you would like to purchase it in DVD format, please go to Andrew #39;s website http://www.checktheevidence.co.uk, where you will also find more of Andrew #39;s research and other interesting videos evidence Lloyd Pye - Starchild Skull - The New Evidence - Lloyd, who has worked as a Hollywood Screen Writer, author and lecturer, is a long time researcher into Hominids and Hominoids, will be discussing the world-famous Starchild Skull, a real bone skull found in Mexico in 1930. Lloyd illustrates 25 major physical differences between the Starchild and a normal human skull. He shows that several parts of the Starchild are not seen in any other skulls or bones on planet Earth! Most importantly, he delves into recent research on the Starchild #39;s DNA, which clearly shows that as soon as its entire genome is recovered and sequenced, its genetics will confirm it is vastly more distant from humans than are chimps or gorillas. The Starchild Skull represents history about to be made as big and as important as history can be made, so don #39;t miss this personal introduction to a relic that will establish once and for all that we humans are not alone in the universe....and never have been! See http://www.starchildproject.com for more information about the ...

By: Truthjuice Birmingham

Link:
Starchild Skull The New Evidence Lloyd Pye - Video

Recommendation and review posted by Bethany Smith

Gary Taubes says its IMPOSSIBLE for Ectomorphs to gain weight?
Why its IMPOSSIBLE for Ectomorphs to gain weight? People often say to me #39;DURIANRIDER! DIET has NOTHING to do with body composition and its ALL just genetics like Gary Taubes author of #39;why we get fat #39;. Ironically Gary Taubes yo yo #39;s with his weight even. Reality is DIET has EVERYTHING to do with your body fat and fluid levels. Sport is about 20% of that IMHE.

By: durianriders

Read more here:
Gary Taubes says its IMPOSSIBLE for Ectomorphs to gain weight? - Video

Recommendation and review posted by Bethany Smith

Chromosome 11 Genetics
Our project for Genetics Analysis~ CHROMOSOME 11!!! Poolesville High School BY: XYZ Team (Xinyi, Ying, Zihan) Original Song: Believe - UKiss 😀 Animation- Xinyi Lyrics- Ying Vocal- Zihan

By: Ying Ngo

Go here to read the rest:
Chromosome 11 Genetics - Video

Recommendation and review posted by Bethany Smith

Fat Burning Exercises to Lose Belly Fat Fast for Men
#9658; #9658;goo.gl #9658; #9658;goo.gl #9658; #9658;goo.gl Watch My Full Video http://www.youtube.com Fat Burning Exercises to Lose Belly Fat Fast for Men diet, plus antifungals and probiotics. Thanks everyone! I wish I could post to his website directly, but I don #39;t know if that is allowed since we aren #39;t supposed to drop the names of doctors on here and it is the site for his clinic. He has almost all his alternative therapies listed on there, but none of them seem to target thyroid specifically. I will go back on and look for the ones mentioned here though. Citations may include links to full-text content from PubMed Central and publisher web sites. PubChem Substance All Chemicals Bioassays Resources. DNA RNA BLAST Basic Local Alignment Search Tool . Data Software BLAST Basic Local Alignment Search Tool . Splign Vector Alignment Search Tool VAST . Conserved Domain Search Service CD Search . Database of Genotypes and Phenotypes dbGaP . Map Viewer Online Mendelian Inheritance in Man OMIM . Bookshelf Database of Genotypes and Phenotypes dbGaP . RefSeqGene All Genetics Medicine Resources. Genomes Maps Database of Genomic Structural Variation dbVar . Homology BLAST Basic Local Alignment Search Tool . BLAST Link BLink Conserved Domain Database CDD . Conserved Domain Search Service CD Search . Protein Clusters All Homology Resources. Sequence Analysis BLAST Basic Local Alignment Search Tool . BLAST Link BLink Conserved Domain Search Service CD Search . Variation Database of Genomic Structural ...

By: MyWLossStory

Read more:
Fat Burning Exercises to Lose Belly Fat Fast for Men - Video

Recommendation and review posted by Bethany Smith

Santosh Yajnik MD Radiation Oncology Consultants Chicagocancer.org
Dr. Yajnik is the Medical Director and primarily practices at Advocate Illinois Masonic Medical Center. He attended both college and medical school at the University of Chicago and did his residency training at the Memorial Sloan-Kettering Cancer Center in New York. Dr. Yajnik has conducted research in the areas of prostate brachytherapy, radiation therapy for thoracic tumors, and gene therapy for prostate cancer. He has written numerous papers and made presentations locally and nationally. In 2004, his research on prostate brachytherapy was presented at the American Brachytherapy Society meeting in Barcelona, Spain. In both 2005 and 2010, Dr. Yajnik has served as an American Society for Therapeutic Radiology and Oncology (ASTRO) representative on the collaborative subcommittee that revised the guidelines "ACR Practice Guidelines for the Performance of Stereotactic Radiosurgery". Dr. Yajnik served on the ASTRO Information Technology Development Resource Committee in 2008-2009 and served on the ASTRO Communications Committee in 2009-2010. Dr. Yajnik has been in private practice with Radiation Oncology Consultants since 2004. Dr. Yajnik is trained in the use of 3-dimensional conformal radiation therapy, intensity modulated radiation therapy (IMRT), stereotactic radiosurgery, high dose rate brachytherapy, intraoperative radiation therapy, and permanent interstitial brachytherapy (seed implants). He has interest in treating a broad range of cancers including lung ...

By: Ramji Rajendran

See the rest here:
Santosh Yajnik MD Radiation Oncology Consultants Chicagocancer.org - Video

Recommendation and review posted by Bethany Smith

Annual Review 2012 - Gene Therapy Trial for Blindness

By: oxford

Read more:
Annual Review 2012 - Gene Therapy Trial for Blindness - Video

Recommendation and review posted by Bethany Smith

Disease is on the run! An incredible advance in the realm of gene therapy has been made by top researchers in the US and Sweden. A single enzyme from a bacterias immune system can effectively be used to locate specific sections of DNA in a living cell. From there, entire genes can be neutralized or replaced with superior sections of DNA. Clearly, we are on the brink of gene therapy becoming a common and highly effective treatment for terrible diseases like AIDS and cancer.

A group of researchers from MIT, the Broad Institute, and Rockefeller University have been able to use bacterial protein-RNA systems to find and disrupt the DNA of a virus. Cas9, an enzyme that can break the bond in nucleotide subunits of the nucleic acids, is used to target specific parts of a genome. When it finds a match, the Cas9 effectively cuts that segment of DNA. From there, it either leaves the gene non-functional, or allows the researchers to insert replacement DNA into the genome. Impressively, this method is highly precise. Unlike previous attempts at snipping out chunks of DNA, this method will only activate if the DNA segment is an exact match.

Meanwhile, researchers at the Howard Hughes Medical Institute, UC Berkeley, and Emmanuelle Charpentier of the Laboratory for Molecular Infection Medicine have published two papers in Science Express explaining their research on the Cas9enzyme. Harvard Professor George Church explains that Cas9 is five times more efficient than the TALEN (Transcription Activator-Like Effector Nucleases) method of gene alteration. While the TALEN and zinc-finger nucleases techniques are useful, they require much more work and are less precise than Cas9. This new method needs only a tiny RNA molecule to be programmed to seek a specific section of DNA.

Once we pinpoint specific genes that cause a disease, Cas9 can be sent in to remove the offending base pairs. Clinical trials using the zinc-finger nucleases method are being performed already, and this breakthrough will provide even more options going forward. Feng Zhang, an MIT assistant professor, believes that this can even be used to study disease by causing mutations in healthy cells. Previously fatal diseases can now be targeted and even potentially cured. Correcting defective genes and stomping out rogue viruses are on the table now, and its only a matter of time before gene therapy becomes a common tool like vaccines and antibiotics for physicians.

Now read: Harvard cracks DNA storage, crams 700 terabytes of data into a single gram

Research papers:DOI:10.1126/science.1232033 RNA-Guided Human Genome Engineering via Cas9; DOI: 10.1126/science.1231143 Multiplex Genome Engineering Using CRISPR/Cas Systems; RNA-programmed genome editing in human cells [PDF]

[Image credit: Duncan Hull & Stuart Caie]

View post:
MIT researchers crack cheap, precise gene therapy

Recommendation and review posted by Bethany Smith

St. Bernard Simba's osteoarthritis in his hips, neck and spine has almost immobilized him at just seven years old. Owner, Jennifer McGuire said, "He's extremely painful. He can't get up and down, he can't sit. He can only lay down or stand up, and walking is very painful for him." McGuire is also a technician at the Chattanooga Holistic Animal Institute. They started doing stem cell therapy this week and are the only animal clinic in town doing it. Simba was the first client. "I'm very excited about the technology and very excited about the chance that he may get to live a pain free life," McGuire said. Dr. Colleen Smith says she sees many animals that suffer with arthritis. "Most of your dogs, especially large breed and giant breed dogs I would say almost 89 percent of them have arthritis," said Dr. Smith. She says stem cell therapy is the best treatment out there. "As far as a quality life. That's where I want improvement. I want them to move better and feel better without having the extraneous medicine." Local pet owners got the chance to learn about how the new treatment works. Jason Richardson, National Sales Director of MediVet says it is a one day treatment. "Stem cells are repair cells and it's homing in on inflammation, so we're gonna take these stem cells from the adipose, inject them into these inflammatory environments where these cells can begin to regenerate tissue. So this is one of the first modalities that gets to the root of what's causing the animal's pain," said Richardson. The Chai clinic is already scheduling appointments for pet lovers, and Simba is already starting to feel a little better.

More:
Animal Stem Cell Therapy

Recommendation and review posted by simmons

Jan. 9, 2013 After uncovering a mechanism that promotes chronic intestinal inflammation and the development of colorectal cancer, scientists from Virginia Commonwealth University Massey Cancer Center have found that fingolimod, a drug currently approved for the treatment of multiple sclerosis, could potentially eliminate or reduce the progression of colitis-associated cancer (CAC).

The study, published online in the journal Cancer Cell, was led by Sarah Spiegel, Ph.D., Mann T. and Sara D. Lowry Chair in Oncology, co-leader of the Cancer Cell Signaling program at VCU Massey Cancer Center and chair of the Biochemistry and Molecular Biology Department at the VCU School of Medicine. Spiegel's team discovered that increased production of an enzyme known as sphingosine kinase 1 (SphK1) causes cells lining the intestine to produce more of a signaling molecule known as sphingosine-1-phosphate (S1P), which activates a variety of biological mechanisms that lead to chronic intestinal inflammation and the development and progression of CAC. The researchers then used animal models to demonstrate that the drug fingolimod decreased expression of SphK1 and S1P's receptor, S1PR1, which subsequently interfered with the development and progression of CAC, even after tumors were established.

"Perhaps the most significant aspect of this study is the therapeutic potential of fingolimod in the treatment of colitis-associated cancer," says Spiegel. "Since this drug is already approved for clinical use, we're hoping to initiate a clinical trial to study its efficacy in patients with CAC in combination with approved therapies."

Essentially, the researchers discovered a self-feeding loop that results in chronic intestinal inflammation and increases the progression of CAC. The team showed that increased production of SphK1 and S1P lead to sustained activation of NF-kB and Stat3, which are both proteins called transcription factors that control the way DNA is transcribed in a cell's nucleus in order to respond to environmental stimuli. This increased activation of NF-kB and Stat3 led to an increased production of TNF-a and IL-6, which are small pro-inflammatory molecules secreted by immune system cells. The increased inflammation, in turn, led to increased production of SphK1 and S1P, which continued the malicious cycle.

This is the first time that SphK1 and S1P have been linked to NF-kB, Stat3, chronic inflammation and CAC.

"Because one of the consequences of inflammatory bowel diseases is an increased risk of developing colorectal cancer, the next step in our research is to examine blood samples from patients with irritable bowel syndrome and colitis-associated cancer to measure levels of S1P," says Spiegel. "Colorectal cancer is one of the leading causes of cancer-related deaths, and we're hopeful that this research will lead to more effective treatments."

Spiegel collaborated on this study with Kazuaki Takabe, M.D., Ph.D., and Tomasz Kordula, Ph.D., both members of the Cancer Cell Signaling program at VCU Massey; and Jie Liang; Masayuki Nagahashi, M.D., Ph.D.; Eugene Y. Kim, Ph.D.; Kuzhuvelil B. Harikumar, Ph.D.; Akimitsu Yamada, M.D.; Wei-Ching Huang; Nitai C. Hait, Ph.D.; Jeremy C. Allegood, Ph.D.; Megan M. Price; Dorit Avni, Ph.D.; and Sheldon Milstien, Ph.D., all from VCU Massey Cancer Center and the Department of Biochemistry and Molecular Biology at VCU School of Medicine.

This study was supported by NIH grants R37GM043880, RO1CA61774, U19AIO77435, T32HL094290, P30CA16059 and K12HD055881, a Susan G. Komen for the Cure Research Foundation grant and National Institute of Neurological Disorders and Stroke core grant 5P30NS047463.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

See the original post:
Multiple sclerosis drug may one day treat colorectal cancer

Recommendation and review posted by simmons

AUSTIN, Texas, Jan. 8, 2013 /PRNewswire/ --On Friday, January 4th Celling Biosciences hosted the Austin Cell Therapy Symposium at the downtown Hilton to build awareness and provide a platform for physicians, scientists, policy makers and academia to discuss the impact of cell therapy on global healthcare and the opportunity for the local community in Central Texas. Cell therapy will revolutionize the landscape of medicine by providing viable and affordable treatment options across all disciplines of medicine without the controversy associated with embryonic stem cells.

The keynote speaker for the event was Dr. Arnold I. Caplan, Professor of Biology and Director of the Skeletal Research Center at Case Western Reserve University. Dr. Caplan has published over 390 papers and manuscripts and has long been supported by the National Institute of Health and other non-profit and for-profit agencies for his efforts in trying to understand the development, maturation and aging of cartilage, bone, skin and other mesenchymal cell tissues."I firmly believe that the research and development efforts going on today will change the future of medicine forever. We are only scratching the surface of the potential there is to treat different health issues with cell therapy. It takes a concerted effort by scientists, physicians and commercial entities for patients to ultimately enjoy the benefits. This type of platform provided by Celling Biosciences allows us to effectively progress forward," says Dr. Caplan.

Dr. Carl Gregory from the Texas A&M Regenerative Medicine Institute and Dr. Vivienne Rebel from UT Health Science Center San Antonio both represented local academia in Central Texas. The research being conducted and the recruitment of students trained in these programs are obvious reasons for Texans to keep supporting Governor Perry's efforts to make Texas a leader in the research and commercialization efforts of regenerative cell therapy. Both speakers are leading efforts for research that will one day lead to alternative healthcare options.

Dr. Philippe Hernigou, a leading orthopedic surgeon from France, presented his 20 years clinical experience working with cell therapy in his practice as University of Paris Chief of Orthopedics.Dr. Hernigou is well published in his clinical use of cell therapy and has treated over 2,500 patients utilizing autologous bone marrow derived cells to treat a wide range of orthopedic pathologies. Dr. Hernigou's research on the safety of cell therapy has been accepted and will be presented at the 2013 AAOS, a leading congress for orthopedic surgeons.

Clinicians were also represented by Dr. Scott Spann, an orthopedic surgeon at Westlake Hospital in Austin, who provides care to patients with spinal cord injury.Dr. Spann believes one day cell therapy will be a common option for patients suffering from debilitating health issues like spinal cord injury.A member of the audience and orthopedic surgeon, Dr. Christoph Meyer has been utilizing cell therapy in his practice for years and also believes it is the future of medicine. "Thanks to these efforts, physicians are benefiting from access to the growing body of research based medicine being established in the field of cellular therapy and regenerative medicine.As the technology is developed, it ultimately gives my patients the best care available and this event gives me the opportunity to discuss experiences with world leaders in cell therapy."

Healthcare is going through major changes and cell therapy is going to have many challenges ahead. Julian Rivera, legal healthcare specialist at the Brown McCarroll Law Firm, discussed the impact of the recent challenges in front of the Texas Medical Board which has adopted rules that work with the FDA to help keep Texas revolutionizing cell therapy.Mr. Rivera believes that the legal issues will take time but is optimistic about how the State of Texas has handled the challenges thus far.

"We are fortunate to have industry leaders joining us to discuss the future impact of cell therapy. We are proud to be Texans who are pioneering the way in the global healthcare market place for regenerative cell therapies. Celling Biosciences understands that the cell therapy market is in its infancy which is a key reason why we invest heavily on research and development with our teams of scientists, engineers and registered nurses providing physicians with proven cell centric technologies and techniques that collectively help to recreate the human body's biological environment. It is not about just providing cells to treat patients.We believe with the help of these thought leaders presenting today we will get closer to better understanding how to keep delivering safe, efficacious and cost effective therapies to patients," says Founder and CEO of Celling Biosciences, Kevin Dunworth.

About Celling BiosciencesCelling Biosciences is an Austin based company working closely with world leaders in academia, medicine, scientists and engineers to research and develop innovative technologies in the emerging field of regenerative medicine.Celling's product-offering focuses on autologous adult stem cell therapy and the devices and services that compliment these procedures.For more information please visit: http://www.cellingbiosciences.com.

More:
Celling Biosciences Hosts Austin Cell Therapy Symposium

Recommendation and review posted by Bethany Smith

Scientists have discovered a gene that interferes with the clearance of hepatitis C virus infection. They also identified an inherited variant within this gene, Interferon Lambda 4 (IFNL4), that predicts how people respond to treatment for hepatitis C infection.

Previously, results from genome-wide association studies (GWAS) identified common inherited genetic markers that were associated with response to hepatitis C virus treatment and spontaneous clearance of the infection. Those markers are located on chromosome 19 near a known interferon gene, IFNL3. However, molecular investigations into IFNL3 did not explain the GWAS association with spontaneous virus clearance or treatment response. To find the new gene, the investigators used a technology involving RNA sequencing on human liver cells treated to mimic hepatitis C virus infection.

"By using RNA sequencing we looked outside the box to search for something beyond what was already known in this region. We hit the jackpot with the discovery of a new gene. It is possible that other important genes may be discovered using this approach," said co-lead investigator Ludmila Prokunina-Olsson, Ph.D., of the Laboratory of Translational Genomics in NCI's Division of Cancer Epidemiology and Genetics (DCEG).

The researchers found that the IFNL4 region harbors a variant that is found in two alternative forms. One form, called deltaG, results in a deletion in one of the four bases that comprise DNA. The change creates an alteration known as a frameshift, which produces the IFNL4 protein, while the form without the deletion does not produce IFNL4. By analyzing data from hepatitis C-infected African-Americans and European-Americans participating in clinical studies, the authors found that the presence of the IFNL4 protein is associated with poorer clearance and response to treatment than the form that does not produce IFNL4. The deletion variant is more common in people of African ancestry, which helps partially explain why African-Americans have a lower response to current hepatitis C treatments than patients of Asian and European ancestry.

"Our work fulfills several promises of the genomic era," said NCI's Thomas R. O'Brien, M.D., Infections and Immunoepidemiology Branch, DCEG. "One, a better understanding of biology; two, personalized medicine; and three, new potential treatments. We deliver immediately on the first two. We've identified a new gene that may help us better understand response to viral infection and the new genetic marker may transition to clinical practice because it predicts treatment outcome for African-American patients better than the current genetic test. For the third, the INFL4 protein may be used as a novel therapeutic target for hepatitis C virus infection, and possibly other diseases."

The new gene belongs to what is now a family of four interferon-lambda protein-encoding genes, three of which were discovered more than ten years ago (IFNL1, IFNL2 and IFNL3) The mechanism by which the IFNL 4 protein impairs hepatitis C virus clearance remains unknown. Further studies will explore molecular function of this novel protein in normal and disease conditions.

This study, published online in Nature Genetics, was conducted collaboratively with the National Institute of Diabetes and Digestive and Kidney Diseases at NIH, as well as the U.S. Food and Drug Administration, and a number of universities and research institutions. Funding was provided by NCI grant Z01 CP005782.

See the original post here:
New Gene Affects Clearance of Hepatitis C Virus

Recommendation and review posted by Bethany Smith

Food and Healthcare Press Releases Tuesday January 8, 2013

Bangkok--8 Jan--Urban Beauty Thailand

Thailand Breast reconstruction surgery is an option for women who have had to undergo breast removal due to tumors within the breast. Though removal of a breast will cut down the spreading of cancer by ninety percent, it can be debilitating to have the breasts removed and can follow with psychological and emotional trauma.

Breast reconstruction works through using fat injections and nipple surgery. All parts of the breast can be surgically reconstructed including gummy bear breast implants, which is a leak-proof breast implant, made of gel and silicone. If a leak does occur, the gel would be trapped inside by the shell. Such methods are quality procedures being done by plastic surgeons that have learned the latest methods of breast enhancement surgery. Because these methods are advanced, many believe that such procedures are expensive and this should not be the case.

Those looking to get breast surgery in Thailand should look for plastic surgeons that are high skilled and offer their services at an affordable price. If not satisfied with local prices from other surgeons then Urban Beauty Thailand can help potential clients in finding the right doctor that can help them.

Urban Beauty is a beauty and fashion consulting firm, which also has experience in medical tourism in Thailand. They have professional contracts with accredited hospitals in Thailand who can provide a board certified plastic surgeon who provides implants, breast reconstruction surgery, gummy bear breast implants and silicone breast implants.

This also includes women who may not have breast cancer, but may simply need a breast lift or some other form of surgery pertaining to the breast. Women who have faced trauma to the breast area can also use the services of Thai doctors who are experienced, certified and accustomed to dealing with clients from abroad. Places like Bangkok and Phuket are great places in Thailand that offer breast surgery at affordable rates. The reason so many go to Thailand for breast surgery is because of the high quality and cheap pricing that doctors can offer over there. This is one instance where patients can get quite a deal while still receiving quality work and attentive doctors. People should never believe that with cheap prices also come cheap results. It takes research and some digging to find the right plastic surgeon no matter where they are.

People should always be aware of scam artists and fraudulent doctors that offer services at ridiculously low rates for a little compromise in sanitation and work conditions. There should be no compromise when it comes to safety and health. Instruments should always be clean and the area should be pristine and sanitary. Anyone offering less will pose a danger to anyone who goes under the knife, which could result in sickness, serious injury or death.

There should always be a team of people as the procedure is being done. Potential clients should look into the background of any hospital or doctor offering breast surgery in Thailand. Looking into their background and how many breast procedures they have done will give patients a peace of mind in knowing that they will be taken care of.

The Urban Beauty Thailand is the best company for beauty and surgical treatments. Compare to other companies in the region, all of prices are upfront and has a 100% satisfaction rate which means that we are professionals and experts giving world class service.

Visit link:
Breast Cancer Gene: Understand Your Breast Reconstruction Options

Recommendation and review posted by Bethany Smith

MENLO PARK, Calif., Jan. 8, 2013 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (PACB) provider of the PacBio(R)RS High Resolution Genetic Analyzer, and the University of California, Davis (UC Davis) today announced a partnership for the 100K Pathogen Genome Project. As part of the project, Pacific Biosciences' Single Molecule, Real-Time (SMRT(R)) technology will be used to sequence the genomes from at least 1,000 foodborne pathogen samples to completion, and to elucidate their epigenomes. These bacteria represent major illness-causing pathogens, including Salmonella, Campylobacter, E. coli, Vibrio, and Listeria.

The 100K Genome Project was founded by the U.S. Food & Drug Administration, Agilent Technologies, and the laboratory of Dr. Bart Weimer at UC Davis to create a consortium of partners from around the world that will sequence 100,000 foodborne pathogens using next-generation sequencing. This initiative addresses a significant shortage of bacterial pathogen information for use in designing molecular diagnostics, creates a resource to expand our understanding of infection mechanisms, and constructs a public repository for new insights into bacterial evolution by using large-scale genomics.

Pacific Biosciences' SMRT sequencing technology generates sequence reads an order of magnitude longer than other leading DNA sequencing technologies, thereby facilitating efficient de novo microbial genome assemblies. Long reads are critical for resolving genetic complexity in the assembly and finishing of genomes. The use of SMRT sequencing for the automated finishing of microbial genomes has been demonstrated in multiple recent publications, including for the genetic analysis of the Haitian cholera and German E. coli outbreaks.

The kinetic information acquired during SMRT sequencing can be used to elucidate the epigenome of bacteria. Epigenetic DNA base modifications, such as methylation, play an important role in the phenotypic variation, adaptability and pathogenicity of many bacteria, but they have been difficult to study due to the lack of a sequencing method to detect them. As part of the 100K Genome Project, the epigenomes of the pathogenic strains subjected to SMRT sequencing will be characterized, adding an important dataset to public database repositories.

"SMRT sequencing has been shown to be a powerful technology for the comprehensive determination of microbial genomes and epigenomes," said Dr. Jonas Korlach, Chief Scientific Officer of Pacific Biosciences. "Through the combination of long reads, high consensus accuracy, and the lack of sequencing bias to GC content or sequence contexts, SMRT sequencing harbors the necessary requirements to construct finished genomes in an unbiased, hypothesis-free manner. The ability to detect methylation as part of the sequencing process is unique to SMRT sequencing, and will provide an invaluable resource to illuminate the epigenetic components controlling bacterial pathogenicity."

"We are very pleased to utilize SMRT sequencing as part of the 100K Genome Project," said Bart Weimer, Professor and Director of the 100K Genome Project, "SMRT technology will enable production of complete genomes that will contribute great value toward databases for biological insight, new biomarker discovery, and reference genomes for food pathogen detection. A project of this scale is needed since microbial genome variations, including structural variations, the acquisition and loss of mobile elements, and phages or plasmids, are very difficult or impossible to detect without a de novo sequencing and genome assembly approach, yet they have a significant impact on food safety."

The partnership will entail the sequencing of at least 1,000 samples by the 100K consortium member labs with access to the PacBio RS instrumentation, including pipeline constructions for high-throughput pathogen sequencing, de novo genome assemblies, epigenome determination, and data curation and deposition. Pacific Biosciences will provide technical guidance and training to support these activities, and interface closely with the involved laboratories to assist in the efficient construction of these pipelines.

For more information, please visit http://100kgenome.vetmed.ucdavis.edu/index.cfm and http://www.pacb.com.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (PACB) offers the PacBio(R)RS High Resolution Genetic Analyzer to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT(R)) technology, the company's products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems.

See the article here:
100K Pathogen Genome Project Selects PacBio SMRT(R) DNA Sequencing to Generate High-Quality, Finished Genomes

Recommendation and review posted by Bethany Smith

Public release date: 8-Jan-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, January 8, 2013The world's leading zebrafish researchers contribute to the community's active global efforts to promote science education. Scientific papers, many authored by students in grades K-12, as well as articles highlighting innovative curricula and educational tools, a collection of abstracts (including student, parent, and teacher authors), and an informative report from the recent Zebrafish in Education Workshops are featured in a special issue of Zebrafish, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The special issue is available on the Zebrafish website.

Guest Editors Chris Pierret, PhD, Mayo Clinic (Rochester, MN) and Jamie Shuda, EdD, University of Pennsylvania (Philadelphia), together with Education Editors Jennifer Liang, PhD, University of Minnesota Duluth, and Lara Hutson, PhD, University at Buffalo (New York) have prepared a collection of articles that illustrate the progress made in the zebrafish community in the development and implementation of student-led, inquiry-based active learning opportunities for student scientists and teachers.

"The emphasis is on teaching students how to think, rather than on what to think," says Stephen Ekker, PhD, Editor-in-Chief of Zebrafish and Professor of Medicine at Mayo Clinic, Rochester, MN. "This issue will have a substantial impact well beyond the zebrafish community."

The student-authors research articles are of high scientific quality and relevant to modern scientists in their fields. They focus on new curricula that emphasize an inquiry-based approach and give students the opportunity to learn about the process of science. Many of the projects featured in the 15 abstracts culled from presentations at the 10th International Conference on Zebrafish Development and Genetics (Madison, WI, June 2012) will likely lead to full papers submitted for publication in the coming year.

###

About the Journal

Zebrafish is an authoritative peer-reviewed journal published quarterly in print and online. It is the only peer-reviewed journal to focus on the zebrafish and other aquarium fish species as models for the study of vertebrate development, evolution, toxicology, and human disease. Complete tables of content and a sample issue may be viewed online on the Zebrafish website.

About the Publisher

See the rest here:
Surprising teaching tool in K-12 science education -- Zebrafish research

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/hd2zhs/china_in_vitro) has announced the addition of GlobalData's new report "China In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture" to their offering.

Our new report, China In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture provides key market data on the China In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

Scope

- Market size and company share data for In Vitro Diagnostics market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.

- Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.

- 2011 company shares and distribution shares data for each of the seven market categories.

- Global corporate-level profiles of key companies operating within the China In Vitro Diagnosticsmarket.

- Key players covered include Siemens Healthcare, Sysmex Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Shanghai Kehua Bio-engineering Co., Ltd., Beckman Coulter, Inc. and others.

Reasons to buy

Visit link:
Research and Markets: China In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing ...

Recommendation and review posted by Bethany Smith

CHAPEL HILL -- Even if the patients hadnt been as young as 4 months old, the surgery would have been harrowing: six holes bored into the skull, six tiny tubes inserted directly into targeted parts of the brain, then a solution containing hundreds of millions of viruses pumped in.

But the rare degenerative illness it fights is even scarier. Canavan disease strikes infants, essentially making the brain attack itself with a toxic chemical, stopping and reversing development. It then kills, usually before age 10.

The procedure used in the study though, slows Canavans progress and improves and may even help extend their lives, according to a study that appeared last month in the online journal Science Translational Medicine. It does that by using viruses as microscopic trucks to deliver missing genetic material precisely where its needed in the kids brains.

This form of gene therapy was created at UNC-Chapel Hill, and the viral vehicle and genetic cargo used in the study were developed there at the medical schools Gene Therapy Center. Center director R. Jude Samulski was a senior author of the study, which began in 2001 and tracked 13 children who received the treatment.

The youngest was 4 months old, the oldest 83 months when they got the operation. After the procedure, the researchers, led by Paola Leone, an associate professor of cell biology at the University of Medicine and Dentistry of New Jersey, followed them to see how the therapy affected their illness.

To an outsider, the results might not even be noticeable. To the families, though, the changes began quickly and were nothing short of dramatic.

Right away, we saw a significant change in his eyes, said Jordana Holovach of Rye, N.Y., whose son Jacob participated in the study. He then was able to regain some of the strength he had lost in grasping, improved his head control, his immune system clearly got better, and he was even with some assistance able to take steps, something we never thought wed be able to see.

Jacob, who had the operation in 2001, will be 17 years old in February. He has grown so much that he doesnt have the strength to take steps now, but attends a mainstream high school, albeit with substantial help.

Ilyce Randell of Buffalo Grove, Ill., whose son Max was diagnosed when he was little more than 4 months old, said that he hadnt seemed to use his eyes at all before the operation, which he had when he was 3 years old. Not long after it, though, he clearly was focusing on things, and began using his arms.

To this day, his sight is improving, and he barely needs glasses. Thats a huge thing, when youre trapped in your body, she said.

Read more:
UNC scientists: Using virus to deliver genetic material slows kids' illness

Recommendation and review posted by Bethany Smith

Bharat Book Presents: Cancer Genetics, Inc. - Product Pipeline Analysis
For more information kindly visit on: http://www.bharatbook.com Summary Cancer Genetics, Inc. (CGI) is the leader in the field of personalized medicine. It offers cancer diagnostics and treatments tailoring the specific genetic profile of the individual. The diagnostic assays and products offered by the company are designed to increase treatment efficacy and reduce healthcare costs of the hematological, urogenital and HPV-associated cancers. The products offered by the company include DNA-FISH Probes, CGH Microarrays and Next-Generation Sequencing. The products under development include FISH Probes for the diagnosis of renal cancer, HPV-associated cancer test and Microarrays for the diagnosis of leukamia, ovarian cancer, cervical cancer, bladder cancer, prostate cancer amongst others. The company also offers comprehensive array of integrated laboratory services for the diagnosis of cancer. CGI is headquartered in New Jersey, the US. This report is a source for data, analysis and actionable intelligence on the Cancer Genetics, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and ...

By: Deepa Kamath

Go here to see the original:
Bharat Book Presents: Cancer Genetics, Inc. - Product Pipeline Analysis - Video

Recommendation and review posted by Bethany Smith

Dynamic Workout for Calves - Extended Sets - TheMuscleProgram.com
http://www.themuscleprogram.com https Dynamic Workout for Calves - Extended Sets This is just one of the many calf routines I do. I believe in training calves frequently if you don #39;t have great genetics, or genetically gifted calves (like me). So I train calves several times a week but each time I train calves, I normally use a different workout technique. This seems to keep them growing (or at least prevents them from getting smaller!) My Dynamic Workout for calves involves what I call extended sets which is basically a set that consists of various techniques. The two calf exercises I chose for this workout are: Standing Calf Raises Seated Calf Raises. The Dynamic extended set technique is: 10 strict reps 5+ second hold 10 pump reps Basically the first 10 reps are very strict and you can hold the weight for a second or so at the peak of the movement. Then with no rest you hold the weight up for 5 or so seconds. Again, with no rest, you then pump out 10 quick reps. This allows for more blood flow in the muscle. Try this for your next calf workout! Train with Passion, Jason

By: themuscleprogram1

Read the rest here:
Dynamic Workout for Calves - Extended Sets - TheMuscleProgram.com - Video

Recommendation and review posted by Bethany Smith